So far, mepolizumab (anti-IL-5) is the only biologic authorized by various regulatory agencies (FDA, EMA, and ANVISA) for use in patients with EGPA, at a dose of 300 mg every 4-weeks, with usage restricted to specific situations, depending on the stage or severity of the disease.130. Here, IL5 is linked to eosinophilic granulomatosis with polyangiitis.